Yu-Xin Zheng

Yu-Xin Zheng

Auto-generated profile, based on publicly available information

Yu-Xin Zheng

Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

20 November 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
ZWZhao-Yuan Wang
Zhao-Yuan Wang
YZYu-Xin Zheng
Yu-Xin Zheng
FXFan Xu
Fan Xu
YCYing-Zhe Cui
Ying-Zhe Cui
XCXue-Yan Chen
Xue-Yan Chen
XMXiao-Yong Man
Xiao-Yong Man
Atopic dermatitis (AD) is one of the most common inflammatory skin diseases with complex pathogenesis involving epidermal barrier dysfunction, skin microbiome abnormalities and type-2-skewed immune dysregulation. Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that plays critical roles in various biological processes. However, the role of STAT3 in epidermal keratinocytes in AD remains unclear. In this study, we generated an epidermal keratinocyte-specific Stat3-deficient mouse strain (termed Stat3 cKO mice). After topical 2,4-dinitrochlorobenzene (DNCB) treatment, Stat3 cKO mice developed worsened AD-like skin inflammation with increased Ki67+ cells, decreased filaggrin and loricrin expression, and downregulated S100A9 and LL37. The dominant microbial population in Stat3 cKO mice changed from Ralstonia to Staphylococcus. DNCB-treated Stat3 cKO mice displayed more infiltrating type-2 inflammatory cells, including mast cells, eosinophils, and CD4+T cells, accompanied by increased skin IL-4 and serum IgE levels. Moreover, thymic stromal lymphopoietin (TSLP), mainly produced by keratinocytes, was highly expressed in the ear skin of Stat3 cKO mice and chemoattracted more TSLPR+ cells. TSLP blockade significantly alleviated DNCB-induced AD-like skin inflammation in Stat3 cKO mice. Thus, epidermal keratinocyte-specific STAT3 deficiency can aggravate AD-like skin inflammation in mice, possibly through TSLP dysregulation.

9 January 2024 in Allergy
Verified
Journal Article
Closed access
YZYu‐Xin Zheng
Yu‐Xin Zheng
XCXi‐Bei Chen
Xi‐Bei Chen
ZWZhao‐Yuan Wang
Zhao‐Yuan Wang
SCSui‐Qing Cai
Sui‐Qing Cai
MZMin Zheng
Min Zheng
XMXiao-Yong Man
Xiao-Yong Man

1 June 2024 in Lasers in Medical Science
Verified
Journal Article
Open access
PDF file
JRJiali Ruan
Jiali Ruan
YZYuxin Zheng
Yuxin Zheng
SCSuiqing Cai
Suiqing Cai
Previous clinical studies have shown that pulsed dye laser (PDL) and intense pulsed light (IPL) are effective for treating erythematotelangiectatic rosacea(ETR). This article aims to compare the efficacy and safety of PDL and IPL at three different wavelength bands (broad-band, single-narrow-band, and dual-narrow-band) in treating ETR. Sixty subjects with ETR were randomly categorized into four groups and received one of the following laser treatments: PDL (595 nm), IPL with Delicate Pulse Light (DPL, 500–600 nm), IPL with M22 590 (590–1200 nm), or IPL with M22 vascular filter (530–650 nm and 900–1200 nm). Four treatment sessions were administered at 4-week intervals, with one follow-up session 4 weeks after the final treatment. The efficacy of the four lasers was evaluated by comparing the clinical symptom score, total effective rate, VISIA red area absolute score, and RosaQoL score before and after treatment. The safety was evaluated by comparing adverse reactions such as pain, purpura, erythematous edema, and blister. All 60 subjects completed the study. Within-group effects showed that the clinical symptom score, VISIA red area absolute score, and RosaQoL score of all four groups were significantly reduced compared to before treatment (p < 0.001). Between-group effects showed no statistically significant difference among the four laser groups. Safety analysis showed that all four lasers were safe, but the incidence of blister was higher in the M22 vascular group. Nonpurpurogenic PDL, DPL, M22 590, and M22 vascular were equally effective in treating ETR and were well-tolerated. ClinicalTrial.gov Identifier: NCT05360251.

11 October 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YZYu-Xin Zheng
Yu-Xin Zheng
XCXi-Bei Chen
Xi-Bei Chen
FXFan Xu
Fan Xu
YCYing-Zhe Cui
Ying-Zhe Cui
ZWZhao-Yuan Wang
Zhao-Yuan Wang
XMXiao-Yong Man
Xiao-Yong Man

8 March 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YCYing-Zhe Cui
Ying-Zhe Cui
FXFan Xu
Fan Xu
YZYuan Zhou
Yuan Zhou
ZWZhao-Yuan Wang
Zhao-Yuan Wang
XYXing-Yu Yang
Xing-Yu Yang
XMXiao-Yong Man
Xiao-Yong Man